The lifting of the FDA’s clinical hold on Neurizon’s drug will pave the way for its investigation in the HEALEY-ALS trial.

Italy-based biotech firm NanoPhoria Bioscience has announced the initial closing of its Series A funding round, raising €83.5m ($98m).

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m in the 2025's year to date (YTD), according to GlobalData’s Pharma ...

Chiesi Group and Arbor have formed an exclusive partnership and licensing deal for the latter’s investigational gene editing medicine.

Induced pluripotent stem cells (iPSCs) have the potential to usher in a new era of transformative medical treatments, capable of addressing a wide range of diseases and conditions. We explore the ...

AstraZeneca and Daiichi's Datroway offered significant improvements to overall survival (OS) in immunotherapy-ineligible patients.

This culminated in a $500m funding cut to mRNA vaccine research funding, impacting around 22 projects being run at the Biomedical Advanced Research and Development Authority (BARDA). Grants withdrawn ...

Support services are fundamentally important to CDMS vendor selection. Consider the story of this complex rescue study when evaluating an EDC partner.

Through the FDA's ANDA scheme, drug manufacturers who test and produce their generic medicines on US soil can now seek priority review.

The completion of the Series A marks a fast-moving year for Trogenix, which only emerged from stealth in November 2024. The biotech was founded by 4BIO Capital and Professor Steve Pollard as a ...

Researchers from McMaster University and MIT have discovered a new antibiotic to treat inflammatory bowel diseases (IBD).

Health Canada has approved Santhera Pharmaceuticals’ Agamree (vamorolone) drug for treating Duchenne muscular dystrophy (DMD).